GlassScriptPhysician profile
Karen Callen
NPI 1952459349
$3,353.59
in general payments reported to CMS, 2019-2025
38 companies · $475 in 2025
The $475 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $297 · 2021: $608 · 2022: $431 · 2023: $537 · 2024: $507 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.85 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.63 | 2019-2025 | |
| Coopersurgical, INC. | $250.65 | 2019-2025 | Paragard T 380a |
| Myriad Women'S Health, INC. | $203.73 | 2023 | Myrisk |
| Amgen INC. | $181.80 | 2019-2023 | Prolia, Evenity |
| Ethicon US, LLC | $158.78 | 2021-2025 | Stratafix, Dermabond, Harmonic |
| Organon LLC | $154.12 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $144.14 | 2019-2023 | |
| Hologic Sales and Service, LLC | $130.28 | 2020-2025 | Myosure Tissue Removal Device, Aptima, Acessa Provu System |
| Axonics, INC. | $109.52 | 2024 | Axonics |
| Therapeuticsmd, INC. | $108.42 | 2019-2021 | |
| Pfizer INC. | $105.11 | 2021-2025 | |
| Millicent US INC | $104.67 | 2024-2025 | Intrarosa, Femring |
| Evofem Biosciences, INC. | $88.81 | 2021-2024 | |
| Amag Pharmaceuticals, INC. | $85.77 | 2019 | |
| Merck Sharp & Dohme LLC | $85.41 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $80.13 | 2019-2021 | |
| Biogen, INC. | $76.23 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $65.27 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $62.50 | 2023-2025 | Veozah |
| Medicem INC. | $57.03 | 2021-2022 | |
| Boston Scientific Corporation | $52.00 | 2025 | Axonics |
| Biohaven Pharmaceuticals, INC. | $51.80 | 2021 | |
| Mayne Pharma Commercial LLC | $51.39 | 2022-2023 | |
| Sage Therapeutics, LLC | $49.01 | 2021-2022 | |
| Davol INC. | $48.38 | 2022 | |
| Vertical Pharmaceuticals, LLC | $39.49 | 2019 | |
| Mallinckrodt Enterprises LLC | $31.15 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $26.72 | 2025 | |
| Stryker Corporation | $24.80 | 2023 | Universal Neuro 3 |
| Medtronic, INC. | $21.14 | 2023 | Truclear |
| Mylan Pharmaceuticals INC. | $20.57 | 2021 | |
| Becton, Dickinson and Company | $19.37 | 2021 | |
| Octapharma USA, INC. | $18.75 | 2025 | Fibryga |
| Ascend Therapeutics US, LLC | $18.47 | 2021 | |
| Myriad Genetic Laboratories, INC. | $17.62 | 2021 | |
| Allergan, INC. | $14.18 | 2019 | |
| Agile Therapeutics, INC. | $13.38 | 2021 | |
| Channel Medsystems, INC. | $9.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Callen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.